Related Experiment Video
Updated: Feb 20, 2026

Measuring Cardiac Autonomic Nervous System ANS Activity in Children
Published on: April 29, 2013
Health-related quality of life in Danish children with hereditary angioedema
Insights
Health-related quality of life (HRQoL) in children with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) is generally normal. However, symptomatic children may experience lower HRQoL, requiring clinical attention.
Area of Science:
- Pediatrics
- Immunology
- Genetics
Background:
- Hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) significantly impacts adult quality of life.
- While C1-INH-HAE symptoms often begin in childhood, pediatric HRQoL remains understudied.
Purpose of the Study:
- To assess HRQoL in Danish children with C1-INH-HAE.
- To explore correlations between HRQoL, disease severity, and attack frequency.
Main Methods:
- 14 Danish children (ages 2-18) with C1-INH-HAE completed HRQoL questionnaires.
- Validated instruments included PedsQL, Children's Dermatology Life Quality Index, and visual analog scales.
- Child self-reports were used for ages 5 and older, with parent proxy-reports also collected.
Main Results:
- Pediatric HRQoL scores were comparable to healthy children and superior to those in other pediatric studies.
- Lower HRQoL was observed in children with recent attacks.
- Home therapy correlated with lower HRQoL, higher severity, and more frequent attacks.
Conclusions:
- Children with C1-INH-HAE generally exhibit normal HRQoL, outperforming those with common skin disorders.
- Healthcare providers should monitor HRQoL closely in symptomatic children with C1-INH-HAE.
Background:
The potentially life-threatening disease hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) can have considerable impact on the health-related quality of life (HRQoL) in adult patients. Half the patients with C1-INH-HAE develop symptoms before the age of 10 years. However, the HRQoL in children with C1-INH-HAE is almost unexplored.
Objective:
To investigate HRQoL in Danish children with C1-INH-HAE, including possible correlations to disease severity and attack frequency.
Methods:
All Danish children ages 2-18 years with C1-INH-HAE were invited to complete questionnaires regarding HRQoL; 14 (93%) agreed. Child self-report forms were used for children ages ≥5 years. The instruments used were the PedsQL (Child Self-Report and Parent Proxy-Report forms); the Children's Dermatology Life Quality Index; a nonvalidated, disease-specific quality-of-life questionnaire; and two visual analog scales that rated general health.
Results:
The HRQoL scores in our study were comparable with the normal scores for healthy children and better than the scores in the only other study dedicated to HRQoL in children. Children with recent attacks had lower scores, whereas HRQoL scores were not correlated to overall disease severity or age. Surprisingly, home therapy was associated with lower HRQoL; however, home therapy was also correlated to a higher overall severity score and more frequent attacks. There was a strong child-parent agreement in the PedsQL forms, but scores were independent of whether the child had a family history of C1-INH-HAE or sporadic C1-INH-HAE and whether the parent completing the Parent Proxy-Report form carried the disease.
Conclusion:
Overall, the children assessed on average had a normal HRQoL and better than those with other common skin disorders. However, according to our findings, health care providers should be especially attentive to HRQoL when children with C1-INH-HAE become symptomatic.
More Related Videos
Related Concept Videos
Asthma-III: Symptoms and Complications
Classification of Asthma
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Cardiomyopathy III: Hypertrophic Cardiomyopathy

